Pallares R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich P F, Martin R, Gudiol F
Infectious Disease Service, Hospital de Bellvitge Princeps d'Espanya, Barcelona, Spain.
N Engl J Med. 1995 Aug 24;333(8):474-80. doi: 10.1056/NEJM199508243330802.
Penicillin-resistant strains of Streptococcus pneumoniae are now found worldwide, and strains with resistance to cephalosporin are being reported. The appropriate antibiotic therapy for pneumococcal pneumonia due to resistant strains remains controversial.
To examine the effect of resistance to penicillin and cephalosporin on mortality, we conducted a 10-year, prospective study in Barcelona of 504 adults with culture-proved pneumococcal pneumonia.
Among the 504 patients, 145 (29 percent) had penicillin-resistant strains of S. pneumoniae (minimal inhibitory concentration [MIC] of penicillin G, 0.12 to 4.0 micrograms per milliliter), and 31 patients (6 percent) had cephalosporin-resistant strains (MIC of ceftriaxone or cefotaxime, 1.0 to 4.0 micrograms per milliliter). Mortality was 38 percent in patients with penicillin-resistant strains, as compared with 24 percent in patients with penicillin-sensitive strains (P = 0.001). However, after the exclusion of patients with polymicrobial pneumonia and adjustment for other predictors of mortality, the odds ratio for mortality in patients with penicillin-resistant strains was 1.0 (95 percent confidence interval, 0.5 to 1.9; P = 0.84). Among patients treated with penicillin G or ampicillin, the mortality was 25 percent in the 24 with penicillin-resistant strains and 19 percent in the 126 with penicillin-sensitive strains (P = 0.51). Among patients treated with ceftriaxone or cefotaxime, the mortality was 22 percent in the 59 with penicillin-resistant strains and 25 percent in the 127 with penicillin-sensitive strains (P = 0.64) The frequency of resistance to cephalosporin increased from 2 percent in 1984-1988 to 9 percent in 1989-1993 (P = 0.002). Mortality was 26 percent in patients with cephalosporin-resistant S. pneumoniae and 28 percent in patients with susceptible organisms (P = 0.89). Among patients treated with ceftriaxone or cefotaxime, mortality was 22 percent in the 18 with cephalosporin-resistant strains and 24 percent in the 168 with cephalosporin-sensitive organisms (P = 0.64).
Current levels of resistance to penicillin and cephalosporin by S. pneumoniae are not associated with increased mortality in patients with pneumococcal pneumonia. Hence, these antibiotics remain the therapy of choice for this disease.
耐青霉素的肺炎链球菌菌株如今在全球范围内均有发现,并且对头孢菌素耐药的菌株也不断有报道。对于由耐药菌株引起的肺炎球菌肺炎,恰当的抗生素治疗仍存在争议。
为研究对青霉素和头孢菌素的耐药性对死亡率的影响,我们在巴塞罗那对504例经培养证实患有肺炎球菌肺炎的成年人进行了一项为期10年的前瞻性研究。
在这504例患者中,145例(29%)有耐青霉素的肺炎链球菌菌株(青霉素G的最低抑菌浓度[MIC]为0.12至4.0微克/毫升),31例(6%)有耐头孢菌素的菌株(头孢曲松或头孢噻肟的MIC为1.0至4.0微克/毫升)。耐青霉素菌株患者的死亡率为38%,而青霉素敏感菌株患者的死亡率为24%(P = 0.001)。然而,在排除患有多种微生物肺炎的患者并对其他死亡率预测因素进行校正后,耐青霉素菌株患者死亡的比值比为1.0(95%置信区间为0.5至1.9;P = 0.84)。在接受青霉素G或氨苄西林治疗的患者中,24例耐青霉素菌株患者的死亡率为25%,126例青霉素敏感菌株患者的死亡率为19%(P = 0.51)。在接受头孢曲松或头孢噻肟治疗的患者中,59例耐青霉素菌株患者的死亡率为22%,127例青霉素敏感菌株患者的死亡率为25%(P = 0.64)。对头孢菌素的耐药率从1984 - 1988年的2%升至1989 - 1993年期间的9%(P = 0.002)。耐头孢菌素的肺炎链球菌患者的死亡率为26%,敏感菌株患者的死亡率为28%(P = 0.89)。在接受头孢曲松或头孢噻肟治疗的患者中,18例耐头孢菌素菌株患者的死亡率为22%,168例头孢菌素敏感菌株患者的死亡率为24%(P = 0.64)。
目前肺炎链球菌对青霉素和头孢菌素的耐药水平与肺炎球菌肺炎患者死亡率的增加并无关联。因此,这些抗生素仍然是该病的首选治疗药物。